Drug Trial Radar · NCT06252298
A Clinical Study of SCTC21C in Participants With CD38+ Hematologic Malignancies
Last checked: Nov 19, 2026Latest source record: Apr 22, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
74
Planned (sponsor's estimate)
Start
Feb 28, 2024
Primary completion
Aug 28, 2025
Study completion Feb 28, 2027
Sponsor
- Lead sponsor
- Sinocelltech Ltd.Industry
- Sponsor type
- Industry
- First posted
- Feb 9, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety and efficacy of SCTC21C in patients with CD38+ hematologic malignancies
Conditions
- Relapsed or Refractory Hematologic Malignancies
Interventions
SCTC21CBiological
SCTC21C is injected to the participants subcutaneously and is tentatively scheduled to be administered weekly for the first two cycles, once every 2weeks for cycle3-6, and once every 4 weeks thereafter until the occurrence of progressive disease
Primary outcomes
What the sponsor says the trial is designed to measure.
- Treatment-emergent adverse events (TEAEs) and serious adverse event (SAE)Time frame: From the initiation of the first dose to the 45 days after the last dose
- The incidence of dose limiting toxicities (dose-finding stage)Time frame: Cycle 1 (28 days)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Chaoyang Hospital ,Capital Medical University
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.